A systematic review investigating VEGF levels in relation to ROP development and ROP treatment with laser and bevacizumab (an anti-VEGF drug) was conducted in 2017, which included 12 publications but did not include a meta-analysis.4 This evidence concerns the gene VEGFA and retinopathy of prematurity.